Theranostic immunoliposomes for osteoarthritis.
Theranostic immunoliposomes for osteoarthritis.
复制标题
DOI：
10.1016/j.nano.2013.09.004
复制
发表时间：
2014-04
期刊：
影响因子：
--
通讯作者：
Hasty KA
中科院分区：
文献类型：
--
作者：
Cho H;Stuart JM;Magid R;Danila DC;Hunsaker T;Pinkhassik E;Hasty KA
虽然在炎性关节炎的治疗方面已经取得了实质性进展，但骨关节炎（OA）的治疗已经滞后，目前主要是姑息性的，直到关节完全功能障碍，需要进行假体置换。开发OA预防性治疗的一个障碍是缺乏有效诊断疾病并在治疗药物或生物制剂的效果最有可能有效的早期阶段监测其进展的良好工具。我们已经开发了近红外免疫脂质体结合II型胶原抗体用于早期OA的诊断和治疗。这些免疫脂质体结合受损但不正常的软骨。利用这些试剂，我们可以定量暴露的II型胶原蛋白在软骨降解过程中在体内的豚鼠个体关节。免疫脂质体可用于确定小动物中治疗干预的有效性以及用于局部药物递送至OA软骨细胞的载体。II型胶原蛋白的抗体通常被阻止与关节软骨表面结合。由常驻软骨细胞、滑膜细胞或浸润性白细胞分泌的蛋白水解酶降解表面蛋白，并允许抗体进入其中的II型胶原纤维网络。
Although there have been substantial advancements in the treatment of inflammatory arthritis, treatments for osteoarthritis (OA) have lagged and currently are primarily palliative until joints become totally dysfunctional and prosthetic replacement is needed. One obstacle for developing a preventive therapy for OA is the lack of good tools for efficiently diagnosing the disease and monitoring its progression during the early stages when the effect of therapeutic drugs or biologics are most likely to be effective. We have developed near infrared immuno-liposomes conjugated with type II collagen antibody for diagnosis and treatment of early OA. These immuno-liposomes bind to damaged but not normal cartilage. Utilizing these reagents, we can quantitate exposure of type II collagen during cartilage degradation in individual joints in vivo in a guinea pig. Immuno-liposomes could be used to determine the effectiveness of therapeutic interventions in small animals as well as vehicles for localized drug delivery to OA chondrocytes. Antibodies to type II collagen are normally blocked from binding to the surface of the articular cartilage. Proteolytic enzymes secreted by resident chondrocytes, synoviocytes or infiltrating leukocytes degrade the surface proteins and allow access of the antibodies to the type II collagen fibrillar network within.